Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
60505-3802-07 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
81864-0101-30 81864-0101 Momelotinib Ojjaara 200.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Sep 15, 2023 In Use
00310-9501-96 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 23, 2024 In Use
50419-0488-58 50419-0488 Sorafenib Nexavar 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral Dec 20, 2005 In Use
50419-0489-01 50419-0489 Sorafenib Nexavar 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, KIT, RET, RET/PTC, FLT3, CRAF, BRAF Oral Oct 2, 2023 In Use
24979-0715-04 24979-0715 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Dec 1, 2022 In Use
80725-0820-60 80725-0820 Hydroxyurea DROXIA 200.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Sep 11, 2025 In Use
63304-0116-30 63304-0116 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct 20, 2023 In Use
00310-9501-04 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Jun 10, 2026 In Use
13668-0682-30 13668-0682 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Apr 12, 2023 In Use
80739-0812-12 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec 12, 2022 In Use
59572-0730-07 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec 18, 2020 In Use
71332-0008-30 71332-0008 Vepdegestrant VEPPANU 200.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral Jun 16, 2026 In Use
64764-0800-28 64764-0800 MARIBAVIR Livtencity 200.0 mg/1 Ancillary Therapy Miscellaneous Agent CMV Antiviral Oral Nov 23, 2021 In Use
50242-0092-86 50242-0092 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 No Longer Used
69097-0032-74 69097-0032 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 18, 2025 In Use
42291-0939-12 42291-0939 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Apr 23, 2024 In Use
13668-0682-60 13668-0682 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Apr 12, 2023 In Use
51990-0201-06 51990-0201 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC,CRAF, BRAF Oral Dec 1, 2022 In Use
69097-0578-73 69097-0578 nilotinib NILCEYA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
59651-0582-30 59651-0582 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Dec 4, 2024 In Use
72205-0239-63 72205-0239 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 20, 2025 In Use
64764-0800-56 64764-0800 MARIBAVIR Livtencity 200.0 mg/1 Ancillary Therapy Miscellaneous Agent CMV Antiviral Oral Nov 23, 2021 In Use
69097-0032-91 69097-0032 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 18, 2025 In Use
72064-0120-30 72064-0120 avapritinib Ayvakit 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan 9, 2020 In Use

Found 12611 results — Export these results